[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE437878T1 - Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung - Google Patents

Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung

Info

Publication number
ATE437878T1
ATE437878T1 AT06725304T AT06725304T ATE437878T1 AT E437878 T1 ATE437878 T1 AT E437878T1 AT 06725304 T AT06725304 T AT 06725304T AT 06725304 T AT06725304 T AT 06725304T AT E437878 T1 ATE437878 T1 AT E437878T1
Authority
AT
Austria
Prior art keywords
diagnostic imaging
polyaminocarbonic
macrocyclic
application
acid derivatives
Prior art date
Application number
AT06725304T
Other languages
English (en)
Inventor
Marc Port
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Application granted granted Critical
Publication of ATE437878T1 publication Critical patent/ATE437878T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06725304T 2005-03-24 2006-03-24 Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung ATE437878T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0502921A FR2883562B1 (fr) 2005-03-24 2005-03-24 Chelates lipophiles et leur utilisation en imagerie
PCT/EP2006/061034 WO2006100305A2 (fr) 2005-03-24 2006-03-24 Chelates métalliques de dérivés macrocycliques polyaminocarboxyliques et leur utilisation en imagerie diagnostique

Publications (1)

Publication Number Publication Date
ATE437878T1 true ATE437878T1 (de) 2009-08-15

Family

ID=35311843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06725304T ATE437878T1 (de) 2005-03-24 2006-03-24 Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung

Country Status (7)

Country Link
US (1) US8268810B2 (de)
EP (1) EP1885721B1 (de)
AT (1) ATE437878T1 (de)
DE (1) DE602006008135D1 (de)
ES (1) ES2330140T3 (de)
FR (1) FR2883562B1 (de)
WO (1) WO2006100305A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
FR2906806B1 (fr) * 2006-10-09 2012-12-14 Centre Nat Rech Scient Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
EP2067490A1 (de) * 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Chelatbildnerderivate und diese enthaltende Zusammensetzungen zur Verwendung bei Bildgebungsverfahren
FR2939318B1 (fr) * 2008-12-10 2012-07-13 Guerbet Sa Systeme d'encapsulation pour imagerie cest avec quelate q superieur ou egal a 2
FR2968999B1 (fr) * 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980365B1 (fr) * 2011-09-26 2016-02-12 Guerbet Sa Nanoemulsions, leur procede de preparation, et leur utilisation comme agent de contraste.
FR2980364B1 (fr) * 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
EP2892570B1 (de) 2012-09-07 2019-02-27 Bracco Imaging S.p.A Paramagnetische feste lipidnanopartikel zur kernspinnresonanzbildgebung, die amphiphile metallkomplexe enthalten
US10494379B2 (en) 2015-11-26 2019-12-03 Debreceni Egyetem 6-oxa-3,9,15-triaza-bicyclo[9.3.1]pentadeca-1(14),11(15),12-triene derivatives based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents
US10568976B2 (en) 2015-11-26 2020-02-25 Debreceni Egyetem 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents
US10968224B2 (en) 2015-11-26 2021-04-06 Debreceni Egyetem 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents
US20210236664A1 (en) * 2018-04-25 2021-08-05 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
ES2841070T3 (es) 2018-08-06 2021-07-07 Bracco Imaging Spa Agentes de contraste basados en PCTA que comprenden gadolinio
WO2022246183A1 (en) * 2021-05-21 2022-11-24 Northstar Medical Technologies Llc Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
WO2024116053A1 (en) * 2022-11-28 2024-06-06 Novartis Ag Pcta derivatives, conjugates thereof and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154914A (en) 1990-03-12 1992-10-13 Research Corporation Technologies, Inc. Methods of diagnostic image analysis using lipophilic contrast agents
US5242681A (en) 1990-03-12 1993-09-07 Research Corporation Technologies, Inc. Lipophilic contrast agents for diagnostic image analysis
CA2102605A1 (en) 1991-05-23 1992-11-24 Evan C. Unger Liposoluble compounds for magnetic resonance imaging
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
CA2103554C (en) 1991-12-10 2002-07-30 Garry E. Kiefer Bicyclopolyazamacrocyclocarboxylic acid complexes, their conjugates, processes for their preparation, and use as contrast agents
WO1994026315A1 (en) * 1993-05-06 1994-11-24 The Dow Chemical Company Bicyclopolyazamacrocyclocarboxylic acid complexes, their conjugates, processes for their preparation, and use as radiopharmaceuticals
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5614170A (en) 1994-11-30 1997-03-25 Hemagen/Pfc Paramagnetic complexes of N-alkyl-N-hydroxylamides of organic acids and emulsions containing same for magnetic resonance imaging (MRI)
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5833948A (en) 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US5804164A (en) 1996-03-13 1998-09-08 Research Corporation Technologies, Inc. Water-soluble lipophilic contrast agents
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
US6776977B2 (en) 2001-01-09 2004-08-17 Bristol-Myers Squibb Pharma Company Polypodal chelants for metallopharmaceuticals
US7179449B2 (en) 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US7255875B2 (en) 2002-01-24 2007-08-14 Barnes-Jewish Hospital Integrin targeted imaging agents
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
WO2004087656A1 (de) 2003-04-03 2004-10-14 Schering Aktiengesellschaft Konjugate 2,4-ethano- und 2,4-propano-überbrückter 3,6,9-triaza-nonansäure-3n, 6n, 9,9n-tetraessigsäure- und entsprechender phosphorsäuremethylen-derivate und deren abkömmlinge mit biomolekülen, verfahren zu deren herstellung und deren verwendung zur herstellung
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite

Also Published As

Publication number Publication date
US8268810B2 (en) 2012-09-18
EP1885721B1 (de) 2009-07-29
WO2006100305A2 (fr) 2006-09-28
US20090214441A1 (en) 2009-08-27
FR2883562A1 (fr) 2006-09-29
FR2883562B1 (fr) 2009-02-27
ES2330140T3 (es) 2009-12-04
WO2006100305A3 (fr) 2006-11-09
DE602006008135D1 (de) 2009-09-10
EP1885721A2 (de) 2008-02-13

Similar Documents

Publication Publication Date Title
ATE437878T1 (de) Metallchelate von makrocyclischen polyaminocarbonsäurederivaten und deren anwendung bei der diagnostischen bilderzeugung
ATE539060T1 (de) Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
WO2006108405A3 (de) Nanopartikel-wirkstoff-konjugate
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
IL202487A (en) Annals of 5,5 '- (hydroxyalkyl-diethyl) bis (formylazandyl) bis (2,4,6-triiodophenyl preserved), a diagnostic factor containing them and methods of diagnosis and imaging containing these factors
SG158175A1 (en) Lipid complexes coated with peg and their use
EP2402321A3 (de) Chemische Derivate aus Jasmonat, pharmazeutische Zusammensetzungen und Verwendungsverfahren dafür
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
DE602006015929D1 (de) Doxorubicin-immuntest
WO2007002109A3 (en) Multidentate pyrone-derived chelators for medicinal imaging and chelation
CY1113890T1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
EP3000481A3 (de) Peptidvermittelte nicht-kovalente verabreichung von wirkstoffen über die blut-hirn-schranke
WO2009158698A3 (en) Targeted delivery of imaging probes for in vivo cellular imaging
EP2993165A3 (de) Verbindungen mit (substituiertem phenyl-)propenalbestandteil, derivate, biologische aktivität und verwendung davon
WO2009110984A3 (en) Contrast agents for applications including perfusion imaging
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EP3112358A3 (de) 3,6-disubstituierte xanthyliumsalze
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
ATE486284T1 (de) Detektion, überwachung und behandlung von krebs
BRPI0511639A (pt) pirrolidin-2-onas substituìdas
WO2007119029A3 (fr) Co-cristaux de calixarenes et de molecules biologiquement actives
WO2006123937A3 (en) Contrast agents
WO2007121312A3 (en) Trivalent chromium compounds, compositions and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties